Completed PHASE1 INTERVENTIONAL 2-arm NCT00057525

A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Sponsor: DynPort Vaccine Company LLC, A GDIT Company

Conditions Anthrax

Interventions Alhdryogel or PBS Anthrax

Updated 7 times since 2017 Last updated: Jun 29, 2011 Started: Apr 30, 2003 Primary completion: Apr 30, 2004 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Anthrax and is currently completed. DynPort Vaccine Company LLC, A GDIT Company leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DynPort Vaccine Company LLC, A GDIT Company

Data source: DynPort Vaccine Company LLC, A GDIT Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rockville, United States